Segment Reporting - Summary of Segment Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting [Abstract]
CDMO, CRO and Other Third-party Preclinical Studies, Clinical Trials and Consulting Costs	$ 4,812	$ 1,515
License fees, milestone payments, and annual maintenance fees related to acquired technologies		50
Internal research and development personnel expenses	1,069	376
Other research and development costs	149	20
General and administrative personnel expenses	677	209
Other general and administrative expenses	3,647	393
Interest expense	1,443	78
Other segment items	(1,601)	766
Net loss and comprehensive loss	$ (10,196)	$ (3,407)